Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q15326
UPID:
ZMY11_HUMAN
Alternative names:
Adenovirus 5 E1A-binding protein; Bone morphogenetic protein receptor-associated molecule 1; Protein BS69
Alternative UPACC:
Q15326; B2R6G8; B7Z293; F6UH50; Q2LD45; Q2LD46; Q2LD47; Q2LD48; Q5VUI1; Q8N4B3
Background:
Zinc finger MYND domain-containing protein 11, also known as Adenovirus 5 E1A-binding protein, Bone morphogenetic protein receptor-associated molecule 1, and Protein BS69, plays a crucial role in chromatin reading. It specifically binds histone H3.3 trimethylated at 'Lys-36', regulating RNA polymerase II elongation and acting as a transcription corepressor. This protein's unique ability to recognize specific histone modifications underlines its importance in gene expression regulation.
Therapeutic significance:
The protein's involvement in Intellectual developmental disorder, autosomal dominant 30, with speech delay and behavioral abnormalities, highlights its potential as a therapeutic target. Understanding the role of Zinc finger MYND domain-containing protein 11 could open doors to potential therapeutic strategies for treating intellectual disabilities and associated behavioral issues.